Welcome to our dedicated page for Retractable Tech news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Tech stock.
Retractable Technologies Inc. (RVP) delivers critical safety solutions through its innovative medical devices, including patented safety syringes that address global healthcare challenges. This news hub provides investors and healthcare professionals with timely updates on corporate developments, regulatory milestones, and market positioning in the medical device sector.
Access authoritative reporting on RVP's financial performance, product innovations, and compliance achievements. Our curated news collection features earnings announcements, manufacturing expansions, and partnerships that demonstrate the company's commitment to infection prevention and medical device safety.
Key updates include quarterly financial disclosures, FDA clearance announcements, international distribution agreements, and advancements in syringe safety technology. Bookmark this page for structured access to press releases and analysis that matter most to stakeholders in medical innovation and healthcare safety.
Retractable Technologies (NYSE American: RVP) has declared dividends for its Series II Class B and Series III Class B Convertible Preferred Stock. Series II will receive $39,050.00 while Series III will receive $18,561.25. Dividends have accrued at $1.00 per share annually, covering April 1, 2024, to June 30, 2024. Payments will be made on July 22, 2024, to shareholders of record as of July 10, 2024.
Retractable manufactures safety medical products, including VanishPoint® syringes and EasyPoint® needles, designed to prevent needlestick injuries and infections. For more details, visit their website.
Retractable Technologies (NYSE American: RVP) reported a net sales decline to $7.6 million for Q1 2024 from $11.0 million in Q1 2023, resulting in a higher operating loss of $3.0 million compared to $2.7 million last year. The decline was mainly due to reduced international syringe sales for COVID-19 vaccinations, while domestic revenues rose by 22.5%. Operating expenses decreased by 12.9%, thanks to new property tax legislation. A new 50% tariff on syringes and needles, set to take effect in Q3 2024, poses a significant risk as over 90% of products were sourced from China. Unrealized gains on investments contributed positively to net income.
